<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489395</url>
  </required_header>
  <id_info>
    <org_study_id>EDO-SP-01-2015</org_study_id>
    <secondary_id>2015-004847-37</secondary_id>
    <nct_id>NCT03489395</nct_id>
  </id_info>
  <brief_title>A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation</brief_title>
  <official_title>A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raffaele De Caterina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hippocrates Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolated reports have indicated that complete Left Atrial or Left Atrial Appendage thrombus&#xD;
      resolution may be achieved also with use of oral Factor Xa inhibitors, which have&#xD;
      demonstrated the same efficacy but a better safety profile compared to warfarin.&#xD;
&#xD;
      The aim of this open-label pilot study is to investigate the percentage of Left Atrial /Left&#xD;
      Atrial Appendage thrombus resolution with edoxaban therapy in patients with non-valvular&#xD;
      atrial fibrillation. The subordinated aim is the design a larger and longer study to compare&#xD;
      edoxaban and warfarin in the same patient population.&#xD;
&#xD;
      With the exception of few case reports, there are no data in the same patient population&#xD;
      referred to antithrombotic treatments other than vitamin K antagonists.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-controlled, open-label, 4 weeks pilot study.&#xD;
&#xD;
      As the main goal of this exploratory study is the estimation of the magnitude of the Left&#xD;
      Atrial /Left Atrial Appendage thrombus resolution with edoxaban, no control group with&#xD;
      vitamin K antagonists has been considered, providing that, for the purpose of this study, the&#xD;
      magnitude of the response of warfarin is satisfactory defined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-controlled, open-label pilot study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with complete thrombus resolution by TEE, evaluated with the following Probe angulations: 0°, 45°-to-60°, 90°.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute variation of thrombus area by TEE evaluation (Probe angulations: 0°, 45-to-60°, 90°)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent variation of thrombus area by TEE evaluation (Probe angulations: 0°, 45-to-60°, 90°)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to electrical cardioversion (when applicable).</measure>
    <time_frame>4 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety analysis - Percentage of bleeding events (telephone assessment)</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety analysis - Percentage of any stroke or peripheral embolism (telephone assessment)</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety analysis - Percentage of any other safety related events (deaths, Serious Adverse Events and Adverse Events).</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Only a descriptive statistical analysis will be performed.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Edoxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.</description>
    <arm_group_label>Edoxaban</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with all the following criteria will be eligible for inclusion in the study&#xD;
        protocol:&#xD;
&#xD;
          1. Signed written informed consent.&#xD;
&#xD;
          2. Males and females ≥ 18 years of age.&#xD;
&#xD;
          3. Female subjects must be post-menopausal (for at least 2 years), surgically sterile,&#xD;
             abstinent, or, if sexually active, be practicing an effective method of birth control&#xD;
             (e.g., prescription oral contraceptives, contraceptive injections, intrauterine&#xD;
             device, double-barrier method, contraceptive patch, male partner sterilization) before&#xD;
             entry and throughout the study; and, for those of childbearing potential, have a&#xD;
             negative serum β-human chorionic gonadotropin pregnancy test at screening.&#xD;
&#xD;
          4. Atrial fibrillation (AF) must be documented by ECG evidence (e.g., 12-lead ECG, rhythm&#xD;
             strip, Holter, pacemaker interrogation) within 30 days before enrolment.&#xD;
&#xD;
          5. Subjects with newly diagnosed atrial fibrillation are eligible provided that:&#xD;
&#xD;
               -  -there is evidence that the atrial fibrillation is non-valvular:&#xD;
&#xD;
               -  -there is ECG evidence on 2 occasions 24 hours apart demonstrating atrial&#xD;
                  fibrillation.&#xD;
&#xD;
          6. Left Atrial or Left Atrial Appendage thrombosis documented by trans-esophageal&#xD;
             echocardiography (TEE)&#xD;
&#xD;
          7. Cardiac failure, Hypertension, Age (x2 ), Diabetes, Stroke (x 2) risk index-VASC score&#xD;
             &gt;1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with all the following criteria will not be eligible for inclusion in the study&#xD;
        protocol:&#xD;
&#xD;
          1. Hemodynamically significant mitral valve stenosis.&#xD;
&#xD;
          2. Prosthetic heart mechanical or biological valve (annuloplasty with or without&#xD;
             prosthetic ring, commissurotomy and/or valvuloplasty are permitted).&#xD;
&#xD;
          3. Transient atrial fibrillation caused by a reversible disorder (e.g., thyrotoxicosis,&#xD;
             pulmonary embolism, recent surgery or myocardial infarction).&#xD;
&#xD;
          4. Known presence of atrial myxoma.&#xD;
&#xD;
          5. Left ventricular thrombus.&#xD;
&#xD;
          6. Active endocarditis.&#xD;
&#xD;
          7. Active internal bleeding.&#xD;
&#xD;
          8. History of condition associated with increased bleeding risk including, but not&#xD;
             limited to:&#xD;
&#xD;
               -  major surgical procedure or trauma within 30 days;&#xD;
&#xD;
               -  clinically significant gastrointestinal bleeding within 6 months;&#xD;
&#xD;
               -  previous intracranial, intraocular, spinal, atraumatic intra-articular bleeding;&#xD;
&#xD;
               -  chronic haemorrhagic disorder;&#xD;
&#xD;
               -  Any neoplasm, including intracranial neoplasm,&#xD;
&#xD;
               -  arteriovenous malformation or aneurysm.&#xD;
&#xD;
          9. Platelet count &lt;90,000/μL at the screening visit.&#xD;
&#xD;
         10. Sustained uncontrolled hypertension: Systolic Blood Pressure ≥180 mmHg or Diastolic&#xD;
             Blood Pressure ≥100 mmHg.&#xD;
&#xD;
         11. Severe, disabling stroke (modified Rankin score of 4 to 5, inclusive within 3 months&#xD;
             or any stroke &lt; 14 days).&#xD;
&#xD;
         12. Transient ischemic attack within 3 days.&#xD;
&#xD;
         13. Any oral anticoagulant therapy at the time of the baseline visit.&#xD;
&#xD;
         14. Treatment with:&#xD;
&#xD;
               -  aspirin &gt;160 mg daily;&#xD;
&#xD;
               -  aspirin plus a thienopyridine within 5 days;&#xD;
&#xD;
               -  intravenous antiplatelets within 5 days;&#xD;
&#xD;
               -  fibrinolytics within 10 days.&#xD;
&#xD;
         15. Anticipated need for therapy with a non-steroidal anti-inflammatory drug in the next 4&#xD;
             weeks.&#xD;
&#xD;
         16. Treatment with a strong inducer of cytochrome P450 and P glycoprotein, such as&#xD;
             ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, lopinavir,&#xD;
             telaprevir, indinavir, conivaptan, clarithromycin or planned treatment during the&#xD;
             study.&#xD;
&#xD;
         17. Other indication for anticoagulant therapy.&#xD;
&#xD;
         18. Hypersensitivity or intolerance to the study drug, including excipients.&#xD;
&#xD;
         19. Women of childbearing potential who do not want adopt a contraceptive method during&#xD;
             the study period and the following 4 weeks.&#xD;
&#xD;
         20. Breast-feeding women during the study period and the following 4 weeks.&#xD;
&#xD;
         21. Anemia (hemoglobin &lt;10 g/dL) at the screening visit.&#xD;
&#xD;
         22. Known significant liver disease (e.g., acute clinical hepatitis, chronic active&#xD;
             hepatitis, cirrhosis), or Alanine aminotransferase or Aspartate aminotransferase &gt;2 x&#xD;
             Upper Level of Normal or total bilirubin &gt;1.5 x Upper Level of Normal.&#xD;
&#xD;
         23. Patients with moderate or severe renal impairment (CrCL &lt;50 mL/min) or patients with&#xD;
             end stage renal disease (CrCL &lt; 15 mL/min) or on dialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaele De Caterina</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi G. d'Annunzio Chieti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Madonna del Soccorso</name>
      <address>
        <city>San Benedetto Del Tronto</city>
        <state>Ascoli Piceno</state>
        <zip>63074</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale generale regionale &quot;F. Miulli&quot;</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <state>Bari</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero S. Maria delle Grazie</name>
      <address>
        <city>Pozzuoli</city>
        <state>Napoli</state>
        <zip>80078</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN S.ANNA e S.SEBASTIANO</name>
      <address>
        <city>Caserta</city>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi G. D'Annunzio</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale P. Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico AO di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>May 1, 2021</last_update_submitted>
  <last_update_submitted_qc>May 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>Raffaele De Caterina</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03489395/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

